CD
Therapeutic Areas
Versatope Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VT-105 | Universal Influenza A | Phase 1 |
Leadership Team at Versatope Therapeutics
CL
Christopher Locher, PhD
Chief Executive Officer & Co-Founder
MP
M. P. Anza Mammen, MD
Chief Medical Officer
AB
Alan Barber
Chief Financial Officer
KS
Kumkum Saxena, PhD
Vice President, Head of Preclinical R&D
JL
Jessica Lee, MS, MPH
Chief Development Officer